Press release
Dry Age-related Macular Degeneration Clinical Trials Analysis 2024: FDA, EMA, & PMDA Approvals, Therapies, Treatment Market, and Companies by DelveInsight | ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, M
Dry Age-related Macular Degeneration Clinical Trials
DelveInsight's 'Dry Age-related Macular Degeneration Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dry Age-related Macular Degeneration therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain.
The Dry Age-related Macular Degeneration pipeline analysis report offers a comprehensive 360° view of emerging drugs for Dry Age-related Macular Degeneration. It examines the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA. This pipeline research delves into business opportunities, challenges, potential future partnerships, strong competitors, and growth strategies.
To know more in detail about Dry Age-related Macular Degeneration pipeline insight, click here: https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dry Age-related Macular Degeneration Overview
Dry Age-related Macular Degeneration (AMD) is a prevalent eye condition affecting older adults, leading to a gradual loss of central vision. It occurs when the macula, a small central portion of the retina responsible for sharp, straight-ahead vision, deteriorates. There are two forms of AMD: dry and wet. Dry AMD, the more common type, progresses slowly and is characterized by the thinning of the macula and the accumulation of drusen (tiny yellow deposits).
Dry AMD advances through three stages: early, intermediate, and late. Early-stage AMD often presents without symptoms, while intermediate AMD might cause mild vision changes. Late-stage AMD can lead to significant central vision loss, impacting daily activities like reading, driving, and recognizing faces.
Risk factors for Dry AMD include aging, genetic predisposition, smoking, high blood pressure, and obesity. Currently, there is no cure for Dry AMD, but lifestyle changes such as a healthy diet rich in leafy greens and regular exercise can help manage the condition. Additionally, vitamins and minerals, specifically the AREDS2 formulation, may slow progression in intermediate and late stages. Ongoing research aims to develop new treatments, with several promising drugs in the pipeline focusing on slowing or halting disease progression.
Some of the Key Highlights from Dry Age-related Macular Degeneration Pipeline Report
• Over 40+ Dry Age-related Macular Degeneration pipeline therapies are in various stages of growth, and their anticipated acceptance in the Dry Age-related Macular Degeneration market would significantly increase market revenue.
• Leading Dry Age-related Macular Degeneration companies such as Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others are evaluating novel Dry Age-related Macular Degeneration treatment drugs candidate to improve the treatment landscape.
• Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020, Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics and others.
• Out of the emerging Dry Age-related Macular Degeneration therapies Eyecyte RPE (Eyestem), OLX301A (OliX Pharmaceuticals), and EYS809 (Eyevensys) are in the early stages of development for Dry AMD treatment.
• In May 2024, Stealth BioTherapeutics Inc announced results of a Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
• In February 2024, Gyroscope Therapeutics Limited announced results of a Phase II, Outcomes Assessor-masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
• On January 13, 2022, ONL Therapeutics, announced that it had closed on its second tranche of the Company's Series B financing. The total proceeds raised in Series B was USD 46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.
Request a sample and discover the recent advances in Dry Age-related Macular Degeneration therapies @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dry Age-related Macular Degeneration Pipeline Analysis: Drug Profile
ALK-001: Alkeus Pharmaceuticals
ALK-001 is a once-daily oral drug candidate in Phase III clinical trials for the treatment of geographic atrophy (advanced form of AMD) and Stargardt disease. Toxic vitamin A aggregates known as "dimers" are known to form rapidly in Stargardt due to a genetic defect or to accumulate with age in the case of dry AMD. These toxic dimers have been linked to the retinal degeneration seen in Stargardt and AMD. Dimers are formed when two molecules of vitamin A combine chemically. ALK-001 is a vitamin A derivative that has been chemically modified to prevent dimerization.
Zimura: Iveric bio
Zimura (avacincaptad pegol) is an investigational drug that targets and inhibits complement protein C5 cleavage and the formation of its downstream fragments, C5a and C5b. Zimura is thought to reduce or slow the chronic inflammation and cell death associated with the retinal ageing process by inhibiting the formation of membrane attack complex (MAC) and inflammasome activity, potentially avoiding or slowing the degeneration of retinal pigment epithelial cells.
Gain more knowledge on emerging Dry Age-related Macular Degeneration drugs @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DRY AMD Pipeline Therapies and Key Companies
• Zimura: IVERIC bio
• ALK-001: Alkeus Pharmaceuticals
• GT005: Gyroscope Therapeutics
• Risuteganib: Allegro Ophthalmics
• GEM103: Gemini Therapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• RPESC RPE 4W: Luxa Biotechnology
• Eyecyte RPE: Eyestem
• OLX301A: OliX Pharmaceuticals
• EYS809: Eyevensys
Learn more about the FDA approved Dry Age-related Macular Degeneration therapies and Dry Age-related Macular Degeneration Clinical Trials @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dry Age-related Macular Degeneration Pipeline Therapeutics Assessment
By Product Type
• Monotherapy
• Combination Therapy
By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibodies
• Peptides
• Polymers
• Small Molecule
• Gene Therapy
Got queries? Reach out for more information on Dry Age-related Macular Degeneration therapeutics: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Dry AMD Pipeline Report
• Coverage: Global
• Key Dry Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others
• Key Dry Age-related Macular Degeneration Pipeline Therapies: ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others
Table of Contents
1. Dry Age-related Macular Degeneration Pipeline Report Introduction
2. Dry Age-related Macular Degeneration Pipeline Report Executive Summary
3. Dry Age-related Macular Degeneration Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Dry Age-related Macular Degeneration Pipeline Therapeutics
6. Dry Age-related Macular Degeneration Pipeline: Late Stage Products (Pre-registration)
7. Dry Age-related Macular Degeneration Pipeline: Late Stage Products (Phase III)
8. Dry Age-related Macular Degeneration Pipeline: Mid Stage Products (Phase II)
9. Dry Age-related Macular Degeneration Pipeline: Early Stage Products (Phase I)
10. Dry Age-related Macular Degeneration Pipeline Therapeutic Assessment
11. Inactive Products in the Dry Age-related Macular Degeneration Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Dry AMD Companies
14. Key Products in the Dry Age-related Macular Degeneration Pipeline
15. Dry AMD Unmet Needs
16. Dry AMD Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Got queries? Reach out for more information on Dry Age-related Macular Degeneration Pipeline Assessment: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-related Macular Degeneration Clinical Trials Analysis 2024: FDA, EMA, & PMDA Approvals, Therapies, Treatment Market, and Companies by DelveInsight | ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, M here
News-ID: 3524168 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Dry
Rising Prevalence Of Dry Eye Conditions Boosts Growth In Dry Eye Products Market …
The Dry Eye Products Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Dry Eye Products Market Size During the Forecast Period?
In recent years, there has been a significant expansion in the market size of dry eye products. The market is projected…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Dry Eye Market - Advancing Eye Wellness: Dry Eye Solutions Revolutionizing Relie …
Newark, New Castle, USA - new report, titled Dry Eye Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dry Eye market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dry Eye market. The report offers an overview of the market, which…
Dry Lubricants Market Size to Hit $ 813.78 Million by 2028 | Dry Lubricants Indu …
According to our experience research team, Dry Lubricants Market was valued at USD 755.42 Million in 2021, and the global Dry Lubricants industry is projected to reach a value of USD 813.78 Million by 2028, at a CAGR of 1.2% during the forecast period 2022-2028
The report is focused on gaining various Dry Lubricants market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining the market growth. Further, the global…
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
Dry Screw Vacuum Pumps
Swam Dry vacuum pumps are the latest development in the vacuum pump industry. They offer a number of advantages over traditional vacuum pump designs. Best process gas blowers. There is “NO OIL / NO WATER” contact with the process vapours, which is why they are considered extremely environmentally friendly.
Visit us for more info - http://swamatics.com/ProductDetails.aspx?prod=Process%20Gas%20Blowers/Gas%20Boosters
The definition of a dry vacuum pump is a pump that does not use any…
